Insider Transactions in Q1 2022 at Biohaven Pharmaceutical Holding CO Ltd. (BHVN)
Insider Transaction List (Q1 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 19
2022
|
George C. Clark VP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
9,375
-20.09%
|
$1,096,875
$117.09 P/Share
|
|
Jan 19
2022
|
George C. Clark VP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,670
+16.43%
|
$243,810
$43.09 P/Share
|
|
Jan 10
2022
|
Kishan Mehta |
BUY
Exercise of conversion of derivative security
|
Direct |
1,875
+14.98%
|
-
|
|
Jan 10
2022
|
Elyse Stock Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Indirect |
937
+14.85%
|
-
|
|
Jan 10
2022
|
George C. Clark VP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
464
-4.56%
|
$59,392
$128.87 P/Share
|
|
Jan 10
2022
|
George C. Clark VP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+8.94%
|
-
|
|
Jan 07
2022
|
Vlad Coric Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,634
-10.98%
|
$593,152
$128.87 P/Share
|
|
Jan 07
2022
|
Vlad Coric Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+19.15%
|
-
|
|
Jan 07
2022
|
William A Jones Jr CCO-Migraine & Common Disease |
SELL
Payment of exercise price or tax liability
|
Direct |
1,631
-10.44%
|
$208,768
$128.87 P/Share
|
|
Jan 07
2022
|
William A Jones Jr CCO-Migraine & Common Disease |
BUY
Exercise of conversion of derivative security
|
Direct |
3,750
+19.35%
|
-
|
|
Jan 07
2022
|
Elyse Stock Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Indirect |
1,000
+18.39%
|
-
|
|
Jan 07
2022
|
Elyse Stock Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,539
-12.19%
|
$196,992
$128.87 P/Share
|
|
Jan 07
2022
|
Elyse Stock Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,250
+20.47%
|
-
|
|
Jan 07
2022
|
James Engelhart Strategic Advisor |
SELL
Payment of exercise price or tax liability
|
Direct |
1,279
-7.54%
|
$163,712
$128.87 P/Share
|
|
Jan 07
2022
|
James Engelhart Strategic Advisor |
BUY
Exercise of conversion of derivative security
|
Direct |
3,250
+16.09%
|
-
|
|
Jan 07
2022
|
George C. Clark VP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
522
-5.38%
|
$66,816
$128.87 P/Share
|
|
Jan 07
2022
|
George C. Clark VP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+9.34%
|
-
|
|
Jan 07
2022
|
John Tilton Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
342
-6.48%
|
$43,776
$128.87 P/Share
|
|
Jan 07
2022
|
John Tilton Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
875
+14.22%
|
-
|
|
Jan 06
2022
|
Vlad Coric Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,854
-15.38%
|
$720,042
$123.86 P/Share
|
|
Jan 06
2022
|
Vlad Coric Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+24.72%
|
-
|
|
Jan 06
2022
|
William A Jones Jr CCO-Migraine & Common Disease |
SELL
Payment of exercise price or tax liability
|
Direct |
2,230
-15.8%
|
$274,290
$123.86 P/Share
|
|
Jan 06
2022
|
William A Jones Jr CCO-Migraine & Common Disease |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+26.16%
|
-
|
|
Jan 06
2022
|
Elyse Stock Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Indirect |
1,250
+26.67%
|
-
|
|
Jan 06
2022
|
Elyse Stock Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,838
-16.39%
|
$226,074
$123.86 P/Share
|
|
Jan 06
2022
|
Elyse Stock Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,750
+25.06%
|
-
|
|
Jan 06
2022
|
James Engelhart Strategic Advisor |
SELL
Payment of exercise price or tax liability
|
Direct |
1,532
-10.06%
|
$188,436
$123.86 P/Share
|
|
Jan 06
2022
|
James Engelhart Strategic Advisor |
BUY
Exercise of conversion of derivative security
|
Direct |
3,750
+19.75%
|
-
|
|
Jan 06
2022
|
Kimberly Gentile SVP, Clinical Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
1,800
-13.38%
|
$221,400
$123.86 P/Share
|
|
Jan 06
2022
|
Kimberly Gentile SVP, Clinical Operations |
BUY
Exercise of conversion of derivative security
|
Direct |
3,750
+21.8%
|
-
|
|
Jan 06
2022
|
Charles Conway Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,800
-7.52%
|
$221,400
$123.86 P/Share
|
|
Jan 06
2022
|
Charles Conway Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,750
+13.55%
|
-
|
|
Jan 06
2022
|
George C. Clark VP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
409
-4.49%
|
$50,307
$123.86 P/Share
|
|
Jan 06
2022
|
George C. Clark VP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
875
+8.76%
|
-
|
|
Jan 06
2022
|
John Tilton Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
551
-11.12%
|
$67,773
$123.86 P/Share
|
|
Jan 06
2022
|
John Tilton Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,250
+20.15%
|
-
|